STOCK TITAN

Ainos Q3 revenue hits $643K; net loss narrows 36%

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Ainos, Inc. (AIMD) reported third-quarter 2026 revenue of $642,889, up 29,567% year over year, and a GAAP net loss of $1,886,074, 36% narrower than a year earlier. GAAP gross margin was 83.4%, versus 78.0%, and operating expenses declined 20.3%. Ainos said revenue was driven by VELDONA licensing and AI Nose semiconductor programs; results also benefited from recognition of a one-time $600,000 initial VELDONA license fee.

After quarter-end, an existing backend semiconductor customer signed a $9 million purchase agreement for 5,000 additional AI Nose systems, with a $4.5 million initial payment due within 60 days of signing. Ainos collected $950,000 in contractual payments after quarter-end. Beginning in Q4 2026, it expects approximately $175,000 in recurring revenue per quarter over three years from the initial $2.1 million AI Nose agreement, under which 1,400 systems were delivered. Ainos also said it has begun discussions to address convertible notes due in 2027.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointQuarterly revenue reached $642,889, up 29,567% year over year.
  • Moderate pointGAAP net loss narrowed 36% to $1,886,074 in Q3.

Negative

  • None.

Filing Explained

Ainos reported 7,554,324 shares outstanding at September 30, 2026, versus 5,822,675 at December 31, 2025, lowering unchanged holders’ proportional ownership.

The results release is furnished, not deemed filed for Section 18 purposes. At September 30, 2026, the balance sheet lists $660,916 in cash and $16,594,900 in current liabilities, including $11,000,000 in convertible notes payable and $2,812,940 in loan payable.

The $11,000,000 convertible-note balance was listed as noncurrent at December 31, 2025 and current at September 30, 2026.

Ainos reported 7,554,324 common shares outstanding at September 30, 2026, compared with 5,822,675 at December 31, 2025; for holders whose share counts did not change, the higher reported total means a smaller fraction of outstanding shares.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Q3 revenue $642,889 Third quarter 2026; $2,167 in Q3 2025; up 29,567% year over year.
GAAP net loss $1,886,074 loss Third quarter 2026; $2,931,702 loss in Q3 2025; 36% narrower year over year.
Non-GAAP adjusted net loss $672,352 loss Third quarter 2026; $1,376,705 loss in Q3 2025; 51% improvement.
GAAP gross margin 83.4% Third quarter 2026; 78.0% in Q3 2025.
Follow-on AI Nose purchase agreement $9 million Agreement signed after quarter-end for 5,000 additional AI Nose systems.
Additional AI Nose systems ordered 5,000 systems Covered by the follow-on purchase agreement signed after quarter-end.
Initial payment under follow-on agreement $4.5 million Due within 60 days of signing.
Expected recurring revenue Approximately $175,000 per quarter Expected beginning in Q4 2026 over the three-year service period for the initial AI Nose agreement.
Adjusted Net Loss financial
"Management defines Adjusted Net Loss as net loss"
Adjusted net loss is the company’s reported net loss after removing one-time, non-cash, or unusual items that management says obscure underlying results, such as restructuring charges, asset write-downs, or stock-based pay. Investors use it to focus on the business’s core profitability — like smoothing out potholes to judge road quality — but should be cautious because choices about what to exclude can make performance look better than it really is.
GAAP gross margin financial
"GAAP gross margin increased to 83.4%"
GAAP gross margin is a financial measure that shows the percentage of revenue remaining after subtracting the costs directly associated with producing goods or services, calculated according to standard accounting rules. It indicates how efficiently a company is turning sales into profit before accounting for other expenses, and higher gross margins generally suggest better profitability potential. This metric helps investors assess a company's pricing power and cost management.
convertible notes financial
"discussions to address convertible-notes due in 2027"
Convertible notes are a type of short-term loan that a company receives from investors, which can later be turned into company shares instead of being paid back in cash. They matter to investors because they offer a way to support a company early on while giving the potential to own a stake in its success if the company grows and later raises more funding.
working capital financial
"support working capital"
Working capital is the money a business has available to cover its daily expenses, like paying bills and buying supplies. It’s like the cash in your wallet that helps you handle everyday costs; having enough ensures the business can operate smoothly without running into money shortages.
Chemical Intelligence technical
"building Chemical Intelligence for Physical AI"
Atmosphere Engine technical
"Atmosphere Engine extends that intelligence"
Revenue $642,889 Up 29,567% year over year
GAAP net loss $1,886,074 loss 36% narrower year over year
Non-GAAP adjusted net loss $672,352 loss 51% improvement year over year
GAAP gross margin 83.4% 78.0% in Q3 2025
Operating expenses $2,220,938 Declined 20.3% year over year
Guidance

Beginning in Q4 2026, approximately $175,000 in recurring revenue per quarter is expected over the three-year service period under the initial $2.1 million AI Nose agreement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were AIMD’s Q3 2026 revenue and GAAP net loss?

AIMD reported revenue of $642,889, up 29,567% year over year, and a GAAP net loss of $1,886,074, 36% narrower than in Q3 2025. Ainos said revenue was driven by VELDONA licensing and AI Nose semiconductor programs.

What are the terms of AIMD’s $9 million AI Nose order?

An existing backend semiconductor customer signed a $9 million purchase agreement for 5,000 additional AI Nose systems, with a $4.5 million initial payment due within 60 days of signing.

What was AIMD’s non-GAAP adjusted net loss in Q3 2026?

Ainos reported non-GAAP adjusted net loss of $672,352 for Q3 2026, compared with $1,376,705 a year earlier, a 51% improvement. Its defined measure excludes share-based compensation, depreciation and amortization, and common stock issued as a special stock bonus; it does not exclude interest or income taxes and is not EBITDA.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001014763 0001014763 2026-11-12 2026-11-12 0001014763 AIMD:CommonStockParValue0.01PerShareMember 2026-11-12 2026-11-12 0001014763 AIMD:WarrantsToPurchaseCommonStockMember 2026-11-12 2026-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 12, 2026

 

AINOS, INC.
(Exact name of registrant as specified in its charter)

 

Texas   001-41461   75-1974352

(State or other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

3050 Post Oak Blvd, Suite 510-T80, Houston, TX 77056

(281) 898-6586

(Address and telephone number, including area code, of registrant’s principal executive offices)

 

 

(Former name or former address if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.01 per share   AIMD   The Nasdaq Stock Market LLC
Warrants to purchase Common Stock   AIMDW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 2.02 Results of Operations and Financial Condition

 

On November 16, 2026, the Company issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of the press release issued by the Company in this connection is furnished herewith as Exhibit 99.1.

 

The information in this Item in this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, regardless of any general incorporation language in such filing.

 

Item 9.01 Financial Statement and Exhibits

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release of Ainos, Inc., dated November 16, 2026.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Ainos, Inc.
   
Date: November 16, 2026 By: /s/ Chun-Hsien Tsai
  Name: Chun-Hsien Tsai
  Title: Chief Executive Officer

 

 

 

Exhibit 99.1

 

Ainos Reports Third Quarter 2026 Results and Highlights Expanding AI Nose Commercial Momentum

 

Q3 revenue rises 29,567% year over year to $642,889; GAAP net loss narrows 36%

 

$9 million follow-on AI Nose order expands semiconductor relationship; $4.5 million initial payment due within 60 days of signing

 

$175,000 in quarterly recurring revenue expected beginning in Q4 from the initial AI Nose deployment

 

Ainos, Inc. (NASDAQ: AIMD, AIMDW) (“Ainos” or the “Company”) today announced financial results for the third quarter ended September 30, 2026, highlighting increased revenue, a narrower net loss and progress in AI Nose semiconductor commercialization and VELDONA licensing. Subsequent to quarter-end, the Company secured an additional $9 million AI Nose order with $4.5 million initial payment due in 60 days, and collected $950,000 contractual payments.

 

Eddy Tsai, Chairman, President and Chief Executive Officer, commented:

 

“Our third-quarter results show progress in translating commercial agreements into revenue. Revenue reached $642,889, up 29,567% year over year, driven by VELDONA licensing and our AI Nose semiconductor program. We delivered 1,400 AI Nose systems under our initial $2.1 million agreement and received initial orders from another semiconductor customer.”

 

“Following quarter-end, our existing backend semiconductor customer signed a $9 million purchase agreement for 5,000 additional AI Nose systems—more than four times the value of the initial agreement. We believe this follow-on order is tangible evidence of customer demand for Chemical Intelligence in semiconductor manufacturing. As we execute the agreement and collect contractual payments, we expect it to support revenue growth and strengthen working capital.”

 

“Our focus is on fulfilling customer commitments, expanding recurring services and directing operating resources toward Chemical Intelligence commercialization. Our chemical dataset grew from more than 1 billion records in September to over 3 billion in October, supporting product refinement and broader applications. Our potential $10 million VELDONA licensing framework provides a partner-funded path for assigned clinical and regulatory development while we retain core platform ownership.”

 

 
 

 

Christopher Lee, Chief Financial Officer of Ainos, added:

 

“Our Q3 2026 results demonstrate progress in both revenue generation and operating discipline. GAAP net loss improved 36% year over year while non-GAAP adjusted net loss improved 51%. GAAP gross margin increased to 83.4% from 78.0% in the third quarter of 2025, while non-GAAP gross margin increased to 83.6% from 78.0%, excluding share-based compensation and depreciation and amortization allocated to cost of revenue. GAAP operating expense declined 20.3% year over year. These improvements benefited from the recognition of the one-time $600,000 initial VELDONA license fee and revenue from AI Nose semiconductor programs.”

 

“Beginning in Q4 2026, we expect the $2.1 million AI Nose agreement to contribute approximately $175,000 in recurring revenue per quarter over the three-year service period, providing a more predictable revenue foundation.”

 

“Following quarter-end, we collected $950,000 from the VELDONA license payment and AI Nose semiconductor commercialization. The $9 million follow-on AI Nose agreement provides for a $4.5 million initial payment within 60 days of signing. We have also begun discussions to address convertible-notes due in 2027. We believe these efforts will strengthen our working capital foundation and support the next phase of order execution.”

 

Q3 2026 Highlights

 

●Delivered 1,400 AI Nose systems to backend semiconductor customer under the $2.1 million, three-year subscription services; expecting $175,000 revenues per quarter beginning Q4 2026 over the service period.

 

●Received initial orders from a front-end semiconductor customer.

 

 
 

 

●Introduced second-generation AI Nose, with software and hardware upgrades designed for continuous sensing in industrial environment.

 

●Surpassed 1 billion real-world chemical records, strengthening the data foundation for model development and application-specific validation.

 

●Secured three Japanese patents covering AI Nose technologies and their integration with robotic systems.

 

●Established a potential $10 million VELDONA licensing framework for two initial indications and conditional additional licensing opportunities. The partner funds assigned clinical and regulatory development; Ainos retains core platform ownership and participation in applicable net sublicensing revenue.

 

●Completed VELDONA technology transfer, triggering the $600,000 initial license fee recognized in Q3 and collected after quarter-end.

 

●Launched Atmosphere Engine, a modular platform designed to generate nitrogen and oxygen from ambient air near the point of use for semiconductor and AI infrastructure applications.

 

●Improved financial performance: Q3 2026 revenue rose 29, 567% year over year to $642,889; GAAP gross margin expanded to 83.4% from 78.0%. GAAP net losses improved 36% year over year.

 

Q4 2026 Developments

 

●Signed a $9 million purchase agreement for 5,000 additional AI Nose systems with the existing backend semiconductor customer. A $4.5 million initial payment is due within 60 days of signing, with the balance payable upon completion and delivery of all equipment.

 

●Collected $950,000 in contractual payments, from VELDONA licensing and AI Nose semiconductor commercialization.

 

●Surpassed 3 billion real-world chemical data points, announced October 30, more than tripling September’s milestone and expanding resources for product and application development.

 

 
 

 

Non-GAAP Financial Measures

 

In addition to results determined in accordance with U.S. GAAP, this press release includes Adjusted Net Loss, a non-GAAP financial measure. Management defines Adjusted Net Loss as net loss, the most directly comparable GAAP measure, adjusted to exclude share-based compensation, depreciation and amortization, and common stock issued as a special stock bonus. Adjusted Net Loss does not exclude interest or income taxes and is not a measure of EBITDA.

 

Management uses Adjusted Net Loss to evaluate trends in cash operating costs. Ainos believes it helps investors assess the cash resources needed to fund its operations. However, share-based compensation is a recurring cost, and Adjusted Net Loss does not reflect equity dilution, cash interest on Ainos’s debt, or capital expenditures. Other companies may calculate similar measures differently. Adjusted Net Loss should not be considered in isolation or as a substitute for net loss or other GAAP measures. A reconciliation of net loss to Adjusted Net Loss for the three and nine months ended September 30, 2026 and 2025 is provided in the tables below.

 

About Ainos, Inc.

 

Ainos, Inc. (NASDAQ:AIMD) is building Chemical Intelligence for Physical AI, giving machines a new way to understand the physical world by turning chemical signals in the air into digital information. Its AI Nose technology enables intelligent systems to sense and interpret changes in their surroundings, while Atmosphere Engine extends that intelligence toward environmental control. Together, they form a sensing-to-control architecture designed to help machines sense, understand, and ultimately optimize their environments across semiconductor manufacturing, robotics, industrial systems, healthcare environments, and other real-world applications where AI increasingly interacts with the physical world. Follow Ainos on X, formerly known as Twitter, @AinosInc, and LinkedIn to stay up to date. Visit Ainos’ media room at https://ainos.suite.accessnewswire.com.

 

Forward-Looking Statements

 

Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the uncertainty of the contemplated collaboration framework and the expected receipt of license fees, manufacturing license fees and other consideration thereunder; our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our licensed indications and product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.

 

Investor Relations

 

ir@ainos.com

 

 
 

 

Ainos, Inc.

Condensed Consolidated Balance Sheets

 

   September 30,   December 31, 
   2026   2025 
   (Unaudited)     
Assets          
Current assets:          
Cash and cash equivalents  $660,916   $417,353 
Accounts receivable   643,064    22 
Inventory, net   243,729    295,565 
Other current assets   522,120    425,859 
Total current assets   2,069,829    1,138,799 
Intangible assets, net   15,843,468    19,226,003 
Property and equipment, net   264,923    343,281 
Other assets   137,717    163,025 
Total assets  $18,315,937   $20,871,108 
           
Liabilities and Stockholders’ Equity          
Current liabilities:          
Contract liabilities  $350,000   $350,000 
Convertible notes payable   11,000,000    - 
Loan payable   2,812,940    - 
Accrued expenses and other current liabilities   2,431,960    728,683 
Total current liabilities   16,594,900    1,078,683 
Convertible notes payable - noncurrent   -    11,000,000 
Other long-term liabilities   -    1,229,843 
Total liabilities   16,594,900    13,308,526 
Commitments and contingencies          
Stockholders’ equity:          
Preferred stock, $0.01 par value; 50,000,000 shares authorized; none issued and outstanding as of September 30, 2026 and December 31, 2025   -    - 
Common stock, $0.01 par value; 300,000,000 shares authorized as of September 30, 2026 and December 31, 2025, 8,714,324 and 6,982,675 shares issued and 7,554,324 and 5,822,675 shares outstanding as of September 30, 2026, and December 31, 2025, respectively   87,143    69,827 
Common Shares to be issued are 2,801 and nil shares as of September 30, 2026 and December 31, 2025, respectively   28    - 
Treasury stock, at cost (1,160,000 shares held as of September 30, 2026 and December 31, 2025)   (1,972,000)   (1,972,000)
Additional paid-in capital   80,309,746    77,234,374 
Accumulated deficit   (76,460,933)   (67,520,328)
Accumulated other comprehensive loss   (242,947)   (249,291)
Total stockholders’ equity   1,721,037    7,562,582 
Total liabilities and stockholders’ equity  $18,315,937   $20,871,108 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 
 

 

Ainos, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

 

   Three months ended September 30,   Nine months ended September 30, 
   2026   2025   2026   2025 
                 
Revenues  $642,889   $2,167   $643,202   $113,037 
Cost of revenues   (106,623)   (477)   (107,439)   (19,647)
Gross profit   536,266    1,690    535,763    93,390 
Operating expenses:                    
Research and development (including amounts of related party of $231,867 and $681,437 for the three and nine months ended September 30, 2026, and $233,564 and $715,249 for the three and nine months ended September 30, 2025, respectively)   1,696,019    1,990,630    5,236,288    5,626,514 
Selling, general and administrative   524,919    795,253    3,666,880    4,159,627 
Total operating expenses   2,220,938    2,785,883    8,903,168    9,786,141 
Loss from operations   (1,684,672)   (2,784,193)   (8,367,405)   (9,692,751)
                     
Non-operating (expenses) income, net:                    
Interest expense   (204,763)   (176,584)   (581,801)   (534,986)
Other income, net   3,361    29,075    8,601    (74,977)
Total non-operating expenses, net   (201,402)   (147,509)   (573,200)   (609,963)
                     
Net loss before income taxes   (1,886,074)   (2,931,702)   (8,940,605)   (10,302,714)
Provision for income taxes   -    -    -    - 
Net loss  $(1,886,074)  $(2,931,702)  $(8,940,605)  $(10,302,714)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 
 

 

Results of Operations reconciliation of GAAP to Non-GAAP Measures

 

   The three months ended September 30,   The nine months ended September 30, 
   2026   2025   2026   2025 
GAAP net loss attributable to stockholders  $(1,886,074)  $(2,931,702)  $(8,940,605)  $(10,302,714)
Adjustments:                    
Stock-based compensation expense   21,305    348,356    2,033,926    1,728,055 
Stock issued for special stock bonus   -    -    -    862,230 
Depreciation and Amortization   1,192,417    1,206,641    3,553,809    3,578,083 
Non-GAAP net loss attributable to stockholders  $(672,352)  $(1,376,705)  $(3,352,870)  $(4,134,346)

 

 

Filing Exhibits & Attachments

5 documents

Keep reading